Patents by Inventor Steve Shih-Lin Huang

Steve Shih-Lin Huang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230016265
    Abstract: A PSMA-specific agent comprising a compound according to Formula I or Formula II: wherein S1 is absent or is an organic spacer group comprising 3-10 carbons; A is an amino acid chain comprising 1 to 5 amino acids wherein at least one of the amino acids is selected from glutamic acid and aspartic acid; S2 is absent or is an organic spacer group comprising 1 to 15 carbons and/or 0 to 2 amino acids; I1 is an imaging group; and I2 is absent or is an imaging group. The PSMA-specific agents can be used to image PSMA within a tissue region and/or for the treatment of a cancer, such as prostate cancer.
    Type: Application
    Filed: October 28, 2020
    Publication date: January 19, 2023
    Inventor: Steve Shih-lin Huang
  • Patent number: 10918741
    Abstract: A PSMA-specific imaging agent comprising a compound according to formula I: are described, wherein S1 is an organic spacer group having from 5 to 30 carbons, A is an amino acid forming a portion of a negatively charged peptide oligomer, n is from 3 to 6, S2 is an organic spacer group having from 5 to 15 carbons, and I is an imaging group, and pharmaceutically acceptable salts thereof. The PSMA-specific imaging agents can be used to image PSMA within a tissue region to guide the treatment of diseases such as prostate cancer.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: February 16, 2021
    Assignee: THE CLEVELAND CLINIC FOUNDATION
    Inventors: Steve Shih-Lin Huang, Warren D. Heston, Xinning Wang
  • Publication number: 20170354748
    Abstract: A PSMA-specific imaging agent comprising a compound according to formula I: are described, wherein S1 is an organic spacer group having from 5 to 30 carbons, A is an amino acid forming a portion of a negatively charged peptide oligomer, n is from 3 to 6, S2 is an organic spacer group having from 5 to 15 carbons, and I is an imaging group, and pharmaceutically acceptable salts thereof. The PSMA-specific imaging agents can be used to image PSMA within a tissue region to guide the treatment of diseases such as prostate cancer.
    Type: Application
    Filed: June 26, 2017
    Publication date: December 14, 2017
    Inventors: Steve Shih-Lin Huang, Warren D. Heston, Xinning Wang
  • Patent number: 9713649
    Abstract: A PSMA-specific imaging agent comprising a compound according to formula I: are described, wherein S1 is an organic spacer group having from 5 to 30 carbons, A is an amino acid forming a portion of a negatively charged peptide oligomer, n is from 3 to 6, S2 is an organic spacer group having from 5 to 15 carbons, and I is an imaging group, and pharmaceutically acceptable salts thereof. The PSMA-specific imaging agents can be used to image PSMA within a tissue region to guide the treatment of diseases such as prostate cancer.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: July 25, 2017
    Assignee: The Cleveland Clinic Foundation
    Inventors: Steve Shih-Lin Huang, Warren D. Heston, Xinning Wang
  • Publication number: 20150209453
    Abstract: A PSMA-specific imaging agent comprising a compound according to formula I: are described, wherein S1 is an organic spacer group having from 5 to 30 carbons, A is an amino acid forming a portion of a negatively charged peptide oligomer, n is from 3 to 6, S2 is an organic spacer group having from 5 to 15 carbons, and I is an imaging group, and pharmaceutically acceptable salts thereof. The PSMA-specific imaging agents can be used to image PSMA within a tissue region to guide the treatment of diseases such as prostate cancer.
    Type: Application
    Filed: January 26, 2015
    Publication date: July 30, 2015
    Inventors: Steve Shih-Lin Huang, Warren D. Heston, Xinning Wang